The bacterium’s capability to bind to human cells is mediated by a specialized surface protein called CbpF, an autotransporter adhesin, which recognizes and binds to CEACAM1 and CEACAM5. These two cell surface receptors are often overexpressed in various cancers, providing an opportunistic docking platform for F. nucleatum. CEACAM1’s role is particularly notable, as it functions not only as an adhesion receptor but also as an inhibitory immune receptor, dampening immune cell activity once engaged. This dual functionality underscores the bacterium’s sophisticated strategy to both anchor and evade host defenses, a phenomenon that until now lacked detailed structural insight.

Employing cutting-edge cryo-electron microscopy techniques, Gao’s team successfully resolved high-resolution three-dimensional structures of the CbpF protein in complex with CEACAM1 and CEACAM5. Remarkably, their findings show that CbpF forms a trimeric assembly, with each monomer binding a single CEACAM molecule, resulting in a symmetric 3:3 stoichiometric complex. This trimeric adhesion complex demonstrates a coordinated multivalent binding mechanism, enhancing the overall strength and specificity of bacterial attachment to host cells, a key factor during colonization and infection.

Beyond this canonical trimer-receptor interaction, the researchers observed additional complex states involving two trimeric CbpF units binding to a CEACAM dimer. This higher-order assembly suggests that F. nucleatum can modulate its adhesion strength dynamically through cooperative receptor clustering. Such adaptability is crucial for bacterial survival within the highly variable microenvironment of the gut and tumor tissue, where mechanical forces and immune pressures constantly fluctuate.

To conceptualize these insights, the researchers proposed a novel “Velcro model” for bacterial adhesion. In this model, the flexible CbpF protein functions analogously to the loop component of Velcro, while the CEACAM receptors act like hooks. This multi-site, reversible interaction system allows the pathogen to fine-tune the adhesion strength at the molecular level, balancing attachment to tumor cells with the ability to detach as needed to navigate the complex physiological landscape. This dynamic regulation mechanism represents a significant leap forward in our understanding of microbial-host cell interactions.

The implications of this discovery extend beyond a mere structural curiosity. Since CEACAM1 engagement suppresses immune activation, F. nucleatum’s binding could directly contribute to immune evasion within the tumor microenvironment, promoting cancer progression and resistance to therapy. Therefore, targeting the CbpF-CEACAM interaction presents an attractive therapeutic strategy to disrupt this malignant crosstalk. Small molecules or antibodies that interfere with the binding interface could restore immune surveillance and hinder bacterial colonization on tumor cells.

This study also highlights the broader significance of bacterial adhesins in pathogenicity. Adhesion is not a static event but a highly regulated process tuned by both mechanical and biochemical cues. The Velcro adhesion paradigm uncovered here may be a generalized strategy among other pathogenic bacteria that interact with host tissues under mechanical stress. Understanding these mechanisms at the atomic level opens new horizons for designing anti-adhesion therapies as alternatives to conventional antibiotics.

From a technical standpoint, the use of cryo-electron microscopy was crucial in resolving these complexes at near-atomic resolution, overcoming challenges posed by the flexible and multimeric nature of the proteins involved. Such structural biology approaches complement biochemical and cellular assays, collectively painting a comprehensive picture of how F. nucleatum physically and functionally exploits host receptors to sustain and advance colorectal cancer.

The collaboration behind this work, involving Renji Hospital and Shanghai Jiao Tong University’s School of Medicine, exemplifies the interdisciplinary effort necessary to tackle complex biomedical problems. Supported by China’s National Key Research and Development Program, this research underscores the global commitment to understanding microbiome-cancer interactions and developing innovative therapeutic interventions.

As colorectal cancer remains a leading cause of cancer-related mortality worldwide, insights into microbial contributions to tumor biology could shift paradigms in oncological treatment. The identification of bacterial factors like CbpF that modulate tumor-immune dynamics provides a fresh perspective on managing cancers traditionally viewed through a solely human genetic lens.

Future directions for this line of research include exploring the in vivo relevance of these interactions using animal models, assessing how the mechanical forces in the gut environment influence adhesion dynamics, and screening for potent inhibitors of the CbpF-CEACAM interaction. Such efforts could lead to the development of novel drugs that complement existing cancer therapies and improve patient outcomes.

In summary, this study offers a detailed molecular explanation for how Fusobacterium nucleatum adheres to colorectal cancer cells through a cleverly orchestrated multivalent interaction using its CbpF adhesin and tumor-overexpressed CEACAM receptors. The elegant Velcro model not only advances our fundamental understanding of bacterial adhesion but also points toward innovative therapeutic strategies to combat cancer-associated bacterial infections and their immunosuppressive effects.

Subject of Research: Not applicable

Article Title: Binding of Fusobacterium nucleatum autotransporter adhesin CbpF to human CEACAM1 and CEACAM5: A Velcro model for bacterium adhesion

News Publication Date: 12-Sep-2025

Web References:
https://doi.org/10.1073/pnas.2516574122

References:
Gao, G.F. et al. Binding of Fusobacterium nucleatum autotransporter adhesin CbpF to human CEACAM1 and CEACAM5: A Velcro model for bacterium adhesion. Proceedings of the National Academy of Sciences, 2025.

Image Credits: Prof. George F. Gao’s group

Keywords:
Cancer treatments; Bacteria; Cancer cells; Adhesion; Host pathogen interactions; Binding partners

A team of researchers, led by Dr. Edgar Engleman, MD, PhD, at Stanford University, has uncovered that EPO, traditionally seen as a hematopoietic growth factor, functions as a critical switch within the immune landscape of cancer. The study, published in the prestigious journal Science on April 24, 2025, demonstrates that by blocking EPO signaling, formerly “cold” tumors—those that evade immune detection—can be converted into “hot” tumors, rich with activated cancer-fighting immune cells, particularly T lymphocytes. This transformation holds profound therapeutic implications, especially when combined with immune checkpoint inhibitors like anti-PD-1 antibodies, such as the commercially available Keytruda.

Cold tumors are a notorious challenge in oncology because their immune-resistant nature allows unchecked cancer growth. Dr. Engleman’s group utilized sophisticated genome editing techniques to develop multiple mouse models of liver cancer that closely mirror human disease, including its genetic mutations, histological features, and response patterns to existing therapies. Leveraging these models, they observed that tumors exhibiting resistance to anti-PD-1 therapy also showed markedly elevated levels of EPO compared to tumors infiltrated by immune cells. This correlation indicated a previously unappreciated role for EPO in fostering an immunosuppressive tumor microenvironment.

Further investigation revealed that tumor-associated hypoxia, a hallmark of many solid tumors, is a driving force behind the increased expression of EPO within cold tumors. Hypoxia stimulates cancer cells to produce signals that elevate EPO levels, which, in turn, act on macrophages within the tumor. These macrophages, once activated by EPO through its receptor, shift towards an immunosuppressive phenotype, actively repelling T cells and quelling their anti-cancer activities. This crosstalk essentially creates an immune-privileged niche, enabling tumors to grow unchecked and resist current immunotherapies.

Strikingly, when the researchers genetically disrupted the tumor cells’ ability to produce EPO, the formerly cold tumors transformed into hot, inflamed tumors, abundant with active T cells. Conversely, artificially elevating EPO levels in hot tumors induced immune suppression, enabling tumor progression. These elegant experiments solidify the causal role of tumor-derived EPO as an immunosuppressive switch, shifting the tumor-immune balance toward immune evasion.

To probe the therapeutic potential of these findings, the team evaluated the combined blockade of the EPO signaling pathway and PD-1. In murine models carrying cold liver tumors, neither anti-PD-1 therapy nor controls alone improved survival beyond eight weeks post tumor induction. However, mice engineered to have macrophages deficient in EPO receptors exhibited significantly extended survival, with 40% alive at 18 weeks after tumor initiation. Strikingly, when these macrophage-specific EPO receptor knockout mice received anti-PD-1 therapy, survival extended to the full duration of the experiment, with complete tumor regression in most cases.

These results underscore that interrupting EPO signaling effectively reactivates the immune system’s ability to recognize and destroy tumors, overcoming one of the major barriers in cancer immunotherapy. Dr. Engleman emphasized that targeting EPO or its receptor could complement existing checkpoint blockade therapies, thus widening the spectrum of cancers responsive to immunotherapy—particularly liver, pancreatic, colorectal, breast, and prostate cancers, which are typically resistant to anti-PD-1 therapy.

The clinical implications extend beyond liver cancer, as analyses of patient tumor databases revealed a consistent association between high EPO expression and poorer survival across multiple tumor types, including kidney, breast, colon, and skin cancers. This highlights EPO’s broader role as a central regulator within the tumor microenvironment’s immune modulation.

Despite the promise, Dr. Engleman cautions against indiscriminate systemic inhibition of EPO due to its essential physiological role in red blood cell production, raising concerns about anemia as a potential side effect. As an alternative, strategies are under exploration to selectively target EPO receptors expressed on tumor-associated macrophages, aiming to disrupt immunosuppression without compromising erythropoiesis. This targeted approach may offer a safer therapeutic window while enhancing immune-mediated tumor clearance.

This discovery also provides a mechanistic explanation for previous clinical observations that administration of EPO to cancer patients with anemia sometimes accelerated tumor growth—a phenomenon that had puzzled clinicians and researchers for years and led to FDA black box warnings on EPO drugs. By elucidating EPO’s immunosuppressive function within tumors, the study reconciles these clinical findings within a comprehensive biological framework.

The interdisciplinary collaboration for this research included contributions from the New York Blood Center and ImmunEdge Inc., a biotechnology company co-founded by Dr. Chiu, the study’s lead author, and Dr. Engleman. Their joint efforts exemplify how academic and industrial partnerships can accelerate the translation of basic scientific insights into therapeutic innovations.

Looking forward, Dr. Engleman and his team are advancing preclinical development of EPO pathway inhibitors and designing clinical strategies to test their efficacy in human cancers. The anticipated integration of EPO receptor blockade with immune checkpoint therapy holds promise to not only improve patient outcomes but also to expand the reach of immunotherapy to presently refractory cancers.

This pioneering research reshapes fundamental concepts in cancer immunity by unveiling an unexpected role for erythropoietin—a decades-old molecule—in modulating tumor immune escape. As the field embraces these insights, the future of cancer treatment may soon harness EPO-targeted strategies to reinvigorate anti-tumor immunity and bring new hope to patients worldwide.

Subject of Research: Animals

Article Title: Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity

News Publication Date: 24-Apr-2025

Conventional antibody treatments primarily utilize Immunoglobulin G (IgG) antibodies. While these IgGs have been effective in many cancers, they have proven insufficient against ovarian cancer. The King’s College team, however, has pioneered the development of treatment using Immunoglobulin E (IgE) antibodies. IgE antibodies are typically associated with allergic reactions and the immune response against parasitic infections. Their unique binding properties to immune cells situated in tissues rather than circulating in the bloodstream present an uncharted territory in cancer treatment, particularly in the context of solid tumors.

This pioneering IgE antibody, termed MOv18, was thoroughly investigated to assess its ability to activate immune cells derived from ovarian cancer patients while effectively altering the tumor microenvironment. In a landscape characterized by immune suppression due to tumor presence, the research illustrated that MOv18 IgE possesses a distinct mechanism of action, capable of counteracting this immune suppression. The crucial finding here is that MOv18 IgE invigorates various immune cell groups to target and destroy cancer cells.

Through a meticulously designed phase Ia clinical trial involving patients who had not responded favorably to conventional therapies, early results indicated that MOv18 IgE not only exhibited safety at low doses but also demonstrated efficacy in shrinking tumors. This clinical milestone signifies a significant advancement in the therapeutic landscape of ovarian cancer, with the research team now striving to elucidate the intricate mechanisms underpinning the treatment’s success.

In a collaborative effort with medical professionals at Guy’s and St Thomas’ NHS Foundation Trust, the team executed a multidisciplinary study focusing on how MOv18 IgE interacts with diverse immune cell populations within the ovarian cancer patient cohort. A critical focus was placed on macrophages, immune cells that are integral to combating infections and eradicating pathogens. However, the tumor environment has a detrimental effect on macrophages, often leading to their reprogramming in a manner that supports tumor growth rather than immune defense.

Extensive prior research carried out in animal models suggested that MOv18 IgE could reactivate and realign these compromised macrophages towards a cancer-fighting agenda. To test this hypothesis in the human realm, researchers obtained macrophages from both healthy donors and cancerous fluid samples extracted from the peritoneal cavity of ovarian cancer patients. This comparative approach allowed the team to study how ovarian cancer influences macrophage function and the potential for IgE to mediate a reversal of this influence.

The results were compelling: ovarian cancer was shown to hinder the immune activity of macrophages, but the introduction of MOv18 IgE was found to effectively bind to and activate these previously suppressed cells. This activation was pivotal, as it not only induced macrophages to kill ovarian cancer cells directly but also reversed their suppressive influence on T cells. T cells are critical for sustaining long-term immune defense against malignancies, and their activation can significantly alter the trajectory of cancer treatment.

Dr. Gabriel Osborn, a key figure in this research when he was a PhD student at King’s, recounted the findings, emphasizing that MOv18 IgE is capable of redirecting macrophages to break free from the tumor-induced suppression. In doing so, it fosters an environment conducive to T cell activation and anti-tumor responses. This discovery is transformative, as it suggests that leveraging IgE-driven stimulation can reinvigorate the immune landscape within tumors, leading to a more robust immune response against cancer.

Following these laboratory results, the research team analyzed tumor biopsies from two trial participants, comparing pre-treatment and post-treatment samples. The findings illuminated a significant increase in both macrophages and T cells in the samples taken after MOv18 IgE treatment, highlighting the recruitment and activation of these immune cells as a vital component of the treatment’s anti-tumor efficacy.

Professor Sophia Karagiannis spoke to the importance of understanding the biological mechanisms of such treatments, expressing a vision of continued research aimed at harnessing the immune system’s power to combat cancer across various patient demographics and tumor types. The team is committed to advancing the therapeutic potential of MOv18 IgE and exploring the broader implications of IgE-based antibodies in cancer immunotherapy.

Dr. Debra Josephs, a consultant oncologist and co-author of the study, reiterated the urgency of expanding our understanding of immune interactions with cancer. Highlighting the clinical relevance of macrophage activation and migration into tumors, she pointed out that unraveling the mechanisms by which MOv18 IgE operates will provide invaluable insights for the development of even more effective cancer therapies.

In conclusion, the research signifies a pivotal step forward in the fight against ovarian cancer and illustrates the potential of utilizing IgE antibodies as a novel therapeutic approach. As the clinical trials continue, the findings pave the way for an enhanced understanding of the immune landscape in tumors, promising improved treatment strategies for patients grappling with this challenging disease.

The implications of this study extend beyond the realm of ovarian cancer treatment; they herald a new era in antibody therapy where harnessing the immune system’s natural mechanisms can unlock revolutionary strategies in the fight against various cancers. Researchers and clinicians alike will keep a keen eye on developments in this field, eagerly anticipating the next breakthroughs that could emerge from this innovative research.

Subject of Research: Novel IgE Antibody Treatment for Ovarian Cancer
Article Title: Novel Immunotherapy: How IgE Antibodies Help Reactivate the Immune Response Against Ovarian Cancer
News Publication Date: [Insert Date Here]
Web References: [Insert Web References Here]
References: [Insert References Here]
Image Credits: [Insert Image Credits Here]

Keywords: Ovarian cancer, IgE antibodies, immune response, cancer treatment, immunotherapy, macrophages, T cells, clinical trials, antibody therapy.

Trogocytosis is a complex process that allows immune cells to exchange cell surface molecules, altering the immune response landscape. This exchange involves the physical interaction between two cells, leading to the transfer of membrane components and proteins. In the context of CAR-T cell therapy, which involves genetically modifying T cells to express CAR molecules that target cancer, understanding this transfer could radically change therapeutic approaches. Researchers have historically struggled to elucidate the mechanisms regulating trogocytosis, specifically in how the transfer of integral membrane proteins occurs.

One of the pivotal findings from this new study is that CAR molecules can be transferred from CAR-T cells to other T cells through this process of trogocytosis, challenging prior assumptions that these molecules required specific receptor binding to facilitate transfer. Stefano Barbera, the postdoctoral researcher who is a first and corresponding author of the study, stated that the study indicates that while direct contact between cells is essential, the transfer of these molecules does not depend on corresponding receptors being present on the recipient cells.

This finding is revolutionary as it discloses a potentially new regulatory mechanism for trogocytosis, one that does not follow the classical receptor-ligand interactions that have characterized much of immunological research to date. The research team has demonstrated that more complex, yet undiscovered mechanisms might govern how immune cells exchange components, potentially influencing therapeutic strategies in CAR-T cell therapy.

The implications of this discovery are manifold. Researchers now have the opportunity to invent CAR molecules tailored with specific attributes to either facilitate or inhibit the trogocytosis process. This level of control could be instrumental in refining the therapeutic outcomes of CAR-T cell therapies through comparative studies of CAR molecules with varying trogocytosis capabilities. Furthermore, a major unresolved question remains: how does the extent of trogocytosis in the CAR-T cell therapy context affect overall treatment efficacy or side effects?

Previous theories suggested that the mere presence of corresponding receptors on target T cells was essential for trogocytosis to occur, which this study has directly contradicted. The researchers’ emphasis on the significance of the membrane region surrounding the transferring molecule suggests novel targets for therapeutic intervention aimed at enhancing CAR-T cell effectiveness.

Moreover, understanding the specific dynamics of trogocytosis could lead to a paradigm shift in the development of next-generation CAR therapies. The inherent ability of these engineered T cells to share functional components with native T cells may not only bolster their anti-tumor activity, but also influence the overall immune environment in which tumors reside. Deciphering these mechanisms neatly aligns with ongoing efforts to enhance personalized cancer treatments and improve patient responsiveness.

As this research continues in the future, a deeper investigation into the biological role of CAR trogocytosis is warranted. Researchers hope to establish whether modulation of this process can help ameliorate treatment side effects commonly associated with CAR-T cell therapy—an area that would address a crucial gap in current cancer therapeutics.

In summary, through the lens of this pioneering study, the nuances of immune cell interaction have opened new avenues for enhancing CAR-T cell therapy. The ability to dictate the dynamics of molecule sharing offers researchers exciting possibilities not only for improving efficacy but also for paving the way towards innovative practices in immunotherapy. The ramifications of such understanding could ultimately lead to more robust treatments for patients battling various forms of cancer and opens the door for significant advancements in personalized medicine.

As researchers at Uppsala University delve deeper into CAR-T cell behavior in tumor environments, a broad spectrum of exciting new research avenues emerges. Future investigations could focus on harnessing the principles outlined in this study, testing modified CAR constructs in advanced model systems, and ultimately taking these findings to clinical trials. The scientific community watches closely, eager to see how these findings will translate from bench to bedside in real-world applications.

In conclusion, the study of CAR-T cell trogocytosis represents an intriguing frontier in cancer treatment research. As our comprehension of these mechanisms evolves, it is likely that we will see a significant transformation in therapeutic strategies that harness the immune system’s own tools for defending against cancer. Indeed, the potential for enhanced CAR-T therapies that are more effective and have fewer side effects is a tantalizing prospect.

Subject of Research: Animals
Article Title: Trogocytosis of Chimeric Antigen Receptors between T cells is regulated by their transmembrane domains
News Publication Date: 31-Jan-2025
Web References: DOI Link
References: Barbera S, Schuiling MJA, Sanjaya NA, Pietilä I, Sarén T, Essand M, Dimberg A.
Image Credits: Credit: Mikael Wallerstedt

Keywords: CAR-T cells, immunotherapy, trogocytosis, cancer treatment, Uppsala University, transmembrane domains, immune response, cancer therapy.